Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Huntington Ingalls Industries reported first quarter fiscal 2026 revenues of $3.1 billion, up 13.4% year-over-year, driven by growth across its shipbuilding and mission technology segments. Despite higher revenues, operating margins declined slightly, leading to net earnings and diluted EPS of $149 million and $3.79 respectively, unchanged from the…
Broadcom is trading like a safe growth name but with meaningful upside if management hits its AI revenue cadence. The company generates ~$29B of free cash flow, has a $1.97T market cap and a stretched P/E near 80, creating a trade opportunity for disciplined buyers. We lay out an entry at $420, a stop at $380 and a target at $545 for a long-term tr…
Coinbase Global said it will reduce its global headcount by roughly 700 employees, about 14% of its workforce as of May 1, 2026, as part of a restructuring aimed at lowering operating costs and aligning the business for the AI era. The company expects the program to be substantially complete in the second quarter of 2026 and estimates total restruc…
IREN Limited said Tuesday it has signed a definitive agreement to acquire Mirantis, a cloud infrastructure and Kubernetes orchestration provider, in a transaction valued at about $625 million paid in IREN ordinary shares. The deal is aimed at strengthening IREN's AI Cloud delivery by improving deployment, monitoring, support and market access for e…
Cellectar Biosciences saw its shares jump 130% in pre-market trading after announcing an oversubscribed financing package that could provide up to $140 million to advance its radiotherapeutic candidate iopofosine I 131 toward a confirmatory study and an FDA accelerated approval filing for Waldenström macroglobulinemia.
Meta Platforms said on May 5 it will extend technology that identifies and places suspected teenage accounts into Teen Account protections to 27 European Union countries and will apply the system to Facebook in the United States, with rollout to the UK and EU planned in June. The company described using advanced AI to analyze profile context and to…
PayPal reported first-quarter results that exceeded analyst expectations as continued consumer spending supported payment volumes. Revenue rose 7% to $8.35 billion and adjusted earnings per share were $1.34, ahead of consensus. Management under new CEO Enrique Lores outlined a reorganization and plans to cut roughly $1.5 billion in costs over the n…
Morgan Stanley upgraded SSAB AB (ST:SSABa) to overweight from equal-weight, increasing its price target to SKr 94 from SKr 73 and placing the stock on its Top Pick list in place of ArcelorMittal. The bank pointed to improving earnings momentum, robust conditions in the U.S. plate market, and a relatively lower sensitivity to energy costs as key dri…
Fiserv, Inc. reported first quarter 2026 GAAP revenue of $5.03 billion, down 2% year-over-year, with organic revenue down 4%. GAAP EPS declined 29%, and adjusted EPS fell 16%. The company confirmed 2026 organic revenue growth guidance of 1%-3% and adjusted EPS between $8.00 and $8.30. Operating margins declined notably compared to prior year period…
Colliers International Group Inc. announced robust first quarter 2026 financial results, with consolidated revenues rising 15% to $1.31 billion and adjusted EBITDA increasing by 8% to $124.8 million. Adjusted EPS grew 5% to $0.91, reflecting the company's diversified professional services platform's resilience amid an uneven operating environment. …
Repligen Corporation reported a robust first quarter 2026 with revenues of $194 million, up 15% year-over-year, and adjusted EPS growth of 23%. The company reiterated its full-year organic revenue growth guidance of 9%-13%, while increasing adjusted EPS guidance to $1.97-$2.05. Key strategic moves include launching a Transformation Office to enhanc…
NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, will release its first quarter 2026 financial results on May 12, 2026, prior to market open. The company will also host a conference call to discuss the results and business update. NeurAxis focuses on the commercialization of its proprietary PENFS technology, I…
Relmada Therapeutics announced presentations of two abstracts related to NDV-01, their sustained-release gemcitabine-docetaxel formulation for non-muscle invasive bladder cancer (NMIBC), at the American Urology Association 2026 event. Phase 2 data in high-risk NMIBC patients showing 9-12 month efficacy results will be presented, alongside a Phase 3…
Arvinas, a biotechnology company specializing in targeted protein degradation therapies, announced it will release its first quarter 2026 financial results on May 12, 2026, accompanied by a corporate update webcast. The company continues advancing multiple clinical-stage investigational drugs, including FDA-approved VEPPANU developed with Pfizer fo…
Ryan Cohen's unsolicited $56 billion proposal for eBay strains GameStop's balance sheet logic and investor patience. With the stock under pressure, deteriorating technicals and heavy short interest, there's a high-probability trade setup to the downside over the next 45 trading days. Entry, stop and target given with clear risk framing.
EVgo Inc. announced strong first quarter 2026 financial results, achieving record revenues of $110 million, a 45% increase year-over-year. The company expanded its public fast charging stalls by 25% to 5,280 and grew network throughput by 10%, reinforcing its leadership in the U.S. EV charging market. Key strategic initiatives include scaling the n…
Ocular Therapeutix announced its first quarter 2026 financial results along with significant clinical progress in its AXPAXLI program for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Key highlights include positive Phase 3 SOL-1 trial results demonstrating superiority over existing anti-VEGF treatment, initiation of the …
Eupraxia Pharmaceuticals reported encouraging EREFS (Endoscopic Reference Score) data from the ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data show that a higher number of esophageal wall injections (20 injections) resulted in significant improvement in inflammation and fibrosis scores, supporting …
NRx Pharmaceuticals initiated commercial manufacturing of its preservative-free ketamine product utilizing an innovative blow-fill-seal process at a US-based facility. The product aims to address ongoing supply shortages in sterile intravenous ketamine, with production capacity supporting significant sales and scalability. This new formulation excl…
Rhythm Pharmaceuticals announced first quarter 2026 financial results featuring $60.1 million in global net product revenue for IMCIVREE, a treatment for acquired hypothalamic obesity (HO) and rare genetic obesity disorders. The company reported a successful U.S. launch post FDA approval, received European Commission authorization expanding indicat…
Fractyl Health, a clinical stage metabolic therapeutics company focused on innovative treatments for obesity and type 2 diabetes, will announce its Q1 2026 financial results and provide business updates on May 12, 2026. Additionally, CEO Dr. Harith Rajagopalan will present at the BofA Securities 2026 Health Care Conference on May 14, 2026.
Climb Bio announces significant progress in the development of budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated immune diseases. Positive topline Phase 1 data shows robust B-cell depletion via a subcutaneous formulation, supporting advancement to patient trials. Clinical trials for primary membranous nephropathy, immune thromb…
Seres Therapeutics announced first quarter 2026 financial results showing a net loss of $19.9 million compared to net income in the prior year period, impacted by absence of payments from the 2024 VOWST sale. The company is nearing clinical data readout from an investigator-sponsored study of SER-155 for immune checkpoint inhibitor-related enteroco…
Sotera Health Company announced that Alton Shader, current CEO of Viant Medical, will become CEO and join the Board of Directors on May 26, 2026, succeeding Michael B. Petras, Jr. Petras will transition to Executive Chairman to support a smooth leadership change. Shader brings over 20 years of medical industry experience with a focus on growth and …
First Watch Restaurant Group, Inc. announced Q1 2026 financial results showing a 17.3% increase in total revenues to $331.0 million and 2.8% same-restaurant sales growth. Despite a net loss of $2.7 million, adjusted EBITDA rose to $27.8 million. The company opened 16 new restaurants and reaffirmed its full-year growth outlook while raising the low …
